Benzoylpaeoniflorin (BP) is a potential therapeutic agent against oxidative stress related Alzheimer's disease[3]. TGP (The totally-amounted glucosides of paeony), which are made up of paeoniflorin, albiflorin, oxypaeoniflorin as well as benzoylpaeoniflorin) treatment lessened the behavior-based loss shown "in the spontaneous motor activity as well as the potential of falling to rotarod test". Pretreatment with TGP markedly improved motor coordination, striatal dopamine and its metabolite levels. TGP can enhance dopaminergic neuron's cell survival in the SNpc in virtue of the activated cAMP/PKA/CREB factor of growth on inhibiting the pathway of second messenger apoptosis as well[4]. TGP has some superior features with immune regulation, gentle effect, many indications and few adverse drug reactions. TGP may be a promising anti-inflammatory and immune drug with soft regulation and has more superiority in the treatment of AIDs[5]. Additionally, paeoniflorin, benzoylpaeoniflorin, mudanpioside C and paeonol can effectively block voltage-operated Ca2+ channels (VOCCs) to exert calcium antagonism[6].
搜索
